A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies	Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm	Recruiting	Phase 1 / Phase 2	2025-11-26		NCT07070323

6 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Beijing GoBroad Hospital	42
Central People's Hospital of Zhanjiang	7
First Affiliated Hospital of Guangxi Medical University	96
Shanghai Liquan Hospital	11
The General Hospital of Western Theater Command	26
Zhaxin Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai	6

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Beijing GoBroad Hospital	Beijing	China	17
Shanghai Liquan Hospital	Shanghai	China	4
The General Hospital of Western Theater Command PLA	Chengdu	China	4
Zhaxin Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai	Shanghai	China	3